GlassScriptPhysician profile
Errol Segall
NPI 1407855190
$6,648.04
in general payments reported to CMS, 2019-2025
31 companies · $1,427 in 2025
The $1,427 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,121 · 2020: $238 · 2021: $75.29 · 2022: $1,235 · 2023: $1,273 · 2024: $1,279 · 2025: $1,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,979.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $838.37 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $727.91 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $717.98 | 2022-2025 | Caplyta |
| Abbvie INC. | $428.31 | 2021-2025 | Vraylar |
| Vanda Pharmaceuticals INC. | $427.07 | 2019-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $404.65 | 2019-2025 | Trintellix |
| Bausch Health US, LLC | $384.30 | 2019-2025 | Aplenzin, Wellbutrin |
| Supernus Pharmaceuticals, INC. | $342.08 | 2022-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $312.90 | 2019-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Axsome Therapeutics, INC. | $238.31 | 2023-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $215.88 | 2019-2022 | |
| Allergan, INC. | $204.90 | 2019-2020 | |
| Corium, LLC | $201.91 | 2022-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $182.04 | 2019-2024 | Uzedy, Austedo Xr |
| Tris Pharma INC | $180.58 | 2019-2025 | Dyanavel Xr |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $177.79 | 2022-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $104.04 | 2019-2023 | Ingrezza |
| Neos Therapeutics, LP | $71.73 | 2019-2024 | Adzenys Xr-Odt |
| Harmony Biosciences LLC | $67.32 | 2025 | |
| Shire North American Group INC | $65.01 | 2019 | |
| Avanir Pharmaceuticals, INC. | $54.00 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $50.97 | 2020 | |
| Ironshore Pharmaceuticals INC. | $46.99 | 2019-2023 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $36.04 | 2024-2025 | Cobenfy |
| Adlon Therapeutics L.P. | $32.93 | 2020 | |
| Vertical Pharmaceuticals, LLC | $32.62 | 2019-2024 | Relexxii |
| Owp Pharmaceuticals, INC. | $25.75 | 2019 | |
| Sage Therapeutics, LLC | $22.22 | 2024 | |
| Avadel Cns Pharmaceuticals, LLC | $20.99 | 2025 | Lumryz |
| Avion Pharmaceuticals | $18.59 | 2023 | Dhivy |
| Aytu Biopharma, INC. | $13.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Errol Segall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.